Agilent Technologies and Singapore’s Nucleic Acid Therapeutics Initiative (NATi) have entered a two-year research collaboration to advance analytical workflows for complex oligonucleotide candidates, focusing on lipid-modified delivery platforms.

• The collaboration aims to develop end-to-end analytical and preparative workflows for lipid-modified oligonucleotides to support delivery beyond liver tissues.
• Laboratory systems involved include UHPLC, mass detection, preparative HPLC, and Seahorse XF technologies to support characterisation, purification, and quality assessment.
• The project is supported through Agilent’s Global Solution Development Centre in Singapore, including training initiatives and access to advanced analytical capabilities.

This summary is based on a press release issued by Agilent Technologies and distributed via PR Newswire.

Image for illustrative purposes only. Source: Canva.

About Ehub365

For Corporate Clients, ehub365 division delivers critical insights into the ASEAN medical sector, covering investments, new services, and practitioner news. 

A member of 365Asia. Our additional group services are Health365, 365Asia, 健康365, 365Sehat, and 365MEC.